Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

Indian CDMO denies manufacturing drug, contract testing lab pulled up for deficiencies, and lessons learned from Sanofi’s warning letter.

How antisense oligonucleotides open up targeted approaches to rare disease treatment.

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

To shareholders – according to an analysis of financial reports from healthcare companies.